23
2020-08
真人直营投注网站 Announces 2020 Interim Results
(August 23, 2020, Hong Kong) 真人直营投注网站 (stock code: 9939.HK, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) is a clinical-stage novel drug developer in China focused on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other indications. The Company was pleased to announce its recent business highlights and the financial results for the six months ended 30 June 2020 (the “Reporting Period”).
21
2020-08
(August 21, 2020, Hong Kong) 真人直营投注网站 (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical”) announced that Kintor Pharmaceutical and Gensun Biopharma Inc., (a holding subsidiary of Zelgen Biopharmaceuticals Co., Ltd. (stock code:688266.SH), hereinafter referred to as “Gensun”) signed an exclusive license agreement to promote the clinical development and commercialization of Gensun’s PD-L1/TGF-βdual-targeting antibody GS19 in Greater China (including the Chinese mainland, Hong Kong, Macau and Taiwan).
04
2020-08
Results of Kintor's Phase Ib Clinical Trials of Pyrilutamide in America
真人直营投注网站 (stock code: 9939.HK, hereinafter referred to as "Kintor" or the "Company") announced that the phase Ib clinical trials of Pyrilutamide (KX-826) against androgenetic alopecia were completed in the United States. All subjects exited the trials. Data analysis, cleaning and summarisation are underway.
30
2020-07
真人直营投注网站 (“Kintor Pharmaceutical” or the “Company”, stock code 9939.HK) announced that the Company has entered a partnership agreement with Alphamab Oncology (stock code: 9966.HK), to jointly develop the combination therapy of ALK-1 monoclonal antibody GT90001 and PD-L1 / CTLA-4 bispecific antibody KN046 in hepatocellular carcinoma (HCC).
19
2020-07
真人直营投注网站 (“Kintor Pharmaceutical” or the “Company”, stock code 9939.HK) announced the completion of patients enrolment according to the clinical protocol for phase II clinical trials (NCT03899467) of Proxalutamide (GT0918) in the United States for treating metastatic castration-resistant prostate cancer (“mCRPC”).
14
2020-07
Kintor to Colloborate with Applied Biology in COVID-19 Study of Proxalutamide
Jiangsu, China, July 12, 2020 - Suzhou Kintor Pharmaceutical, Inc. a wholly-owned subsidiary of 真人直营投注网站 (“Kintor Pharma”, 9939.HK), and Applied Biology, Inc. entered into a clinical trial research agreement ("Research Agreement"), pursuant to which Suzhou Kintor collaborates with Applied Biology to conduct research for Proxalutamide (GT0918) as a treatment for the novel coronavirus disease ("COVID-19"). We believe that this study is an innovative attempt to use anti-androgens as a possible treatment to devastating COVID-19 worldwide pandemic .
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn